Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting ...

Mountainfield Venture Partners and Chengdu, China-based Keymed Biosciences Co. Ltd have partnered to form San Diego-based Timberlyne Therapeutics, which will progress Keymed’s CD-38 monoclonal ...

Aaaa Aaa Aaaaaaa Aa 10,460.0 +18.26% ...

This approval marks a significant step for Keymed, showcasing its potential in the pharmaceutical market. For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.

A Aaa Aaaaaa 66.77 +23.30% ...

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the ...

Stapokibart is under clinical development by KeyMed Biosciences and currently in Phase III for Prurigo. According to GlobalData, Phase III drugs for Prurigo have a 100% phase transition success rate ...